Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salbutamol + guaifenesin is a **combination pharmaceutical drug** consisting of salbutamol, a selective beta-2 adrenoceptor agonist bronchodilator, and guaifenesin, an expectorant. Salbutamol relaxes bronchial smooth muscle to relieve bronchospasm and improve airflow in conditions such as asthma, chronic bronchitis, and emphysema. Guaifenesin decreases the viscosity of bronchial secretions, promoting easier expectoration. The combination is primarily used for **cough associated with mucus congestion** and respiratory disorders characterized by bronchospasm and excessive mucus, including bronchial asthma, chronic bronchitis, and emphysema[1][2][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salbutamol + guaifenesin.